TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7923515

Group type: EXPERIMENTAL
Intervention: High epidural anaesthesia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low epidural anaesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 20
Study: 2902792

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Nifedipine 90 mg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 31119583

Group type: EXPERIMENTAL
Intervention: Diet 2 (10 g kg−1 CDXOS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Diet 3 (108 CFU g−1 L. plantarum CR1T5)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Diet 4 (10 g kg−1 CDXOS + 108 CFU g−1 L. plantarum CR1T5)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (diet 1)
Number of subjects: 80
Study: 29893446

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Loop diuretic
Number of subjects: 942

Group type: COMPARATOR
Intervention: Serum chloride levels
Number of subjects: 942
Study: 28277290

Group type: EXPERIMENTAL
Intervention: Decision aid with patient narratives (Group 1)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Decision aid without patient narratives (Group 2)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Standard information (Control Group 3)
Number of subjects: 210
Study: 26712393

Group type: EXPERIMENTAL
Intervention: Navigation group (n = 47)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (n = 141)
Number of subjects: 188
Study: 22532169

Group type: EXPERIMENTAL
Intervention: Subjective handwriting assessment (micrographia, normal, macrographia)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Subjective handwriting assessment (macrographia)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Subjective handwriting assessment (micrographia)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Objective handwriting metrics
Number of subjects: 66
Study: 20151804

Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD; 20 mg two times a day)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 17531899

Group type: EXPERIMENTAL
Intervention: Treatment of gestational diabetes mellitus (GDM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Screening for postpartum glucose intolerance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attention to risk factors and plasma glucose status
Number of subjects: 0
Study: 16109560

Group type: EXPERIMENTAL
Intervention: Epi-CH (10 mg Epi-CH injected around the primary tumor or biopsy excision 72 h before operation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (10 mg epirubicin solution injected in the same region)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epi-CH
Number of subjects: 60
Study: 12049562

Group type: EXPERIMENTAL
Intervention: Plasma-mediated ablation (PMA)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Monopolar electrosurgery (MES)
Number of subjects: 34
Study: 9527292

Group type: EXPERIMENTAL
Intervention: Back class teaching extension exercises
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional management (Control)
Number of subjects: 75
Study: 7630622

Group type: EXPERIMENTAL
Intervention: Bovine factor VIII derivative (vascular factor, VF)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 2572037

Group type: EXPERIMENTAL
Intervention: Broxaterol (400 micrograms by metered dose inhaler)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Broxaterol (0.5 mg by oral route)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Broxaterol (0.25 mg as nebulizer solution)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Broxaterol (oral and aerosol administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Broxaterol (400 micrograms by aerosol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Terbutaline (500 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fenoterol (400 micrograms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salbutamol (aerosol)
Number of subjects: 0
Study: 835376

Group type: EXPERIMENTAL
Intervention: Ultrasound method for determining effective orifice area
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional catheterization methods
Number of subjects: 10
Study: 31302586

Group type: EXPERIMENTAL
Intervention: Low pre-NAT TILs
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Low pre-NAT TILs in TNBC with RD
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Low post-NAT TILs in TNBC with RD
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Low pre-NAT TILs in HER2+ BC
Number of subjects: 209
Study: 29364767

Group type: EXPERIMENTAL
Intervention: Endovascular therapy plus standard medical therapy
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard medical therapy alone
Number of subjects: 182
Study: 27595680

Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg BID, with a possible reduction to 2.5 mg BID based on certain criteria; single starting dose of 10 mg or 5 mg if down-titrated)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Heparin plus warfarin
Number of subjects: 1500
Study: 24958908

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir-based ART
Number of subjects: 389

Group type: COMPARATOR
Intervention: efavirenz-based ART
Number of subjects: 389
Study: 21884019

Group type: EXPERIMENTAL
Intervention: Mat Pilates training for 16 weeks, 30 min of aerobic exercise followed by 20 min of Pilates.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional cardiac rehabilitation program for 16 weeks, 30 min of aerobic exercise followed by 15 min calisthenics exercise.
Number of subjects: 16
Study: 20043705

Group type: EXPERIMENTAL
Intervention: Telephone peer support (intervention group, n = 38)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No telephone peer support (control group, n = 40)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Telephone peer support (intervention group, n = 13 exclusively breastfeeding at discharge)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No telephone peer support (control group, n = 11 exclusively breastfeeding at discharge)
Number of subjects: 78
Study: 18608712

Group type: EXPERIMENTAL
Intervention: Isotretinoin (Iso) therapy for cystic acne for 45 days
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Isotretinoin (Iso) therapy for cystic acne
Number of subjects: 74
Study: 16182139

Group type: EXPERIMENTAL
Intervention: web SAQ
Number of subjects: 1918

Group type: COMPARATOR
Intervention: paper SAQ
Number of subjects: 1918
Study: 12381942

Group type: EXPERIMENTAL
Intervention: High-dose calcium acetate (1,521 mg calcium/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose calcium acetate (507 mg calcium/day)
Number of subjects: 0
Study: 10195547

Group type: EXPERIMENTAL
Intervention: Flexible Laryngeal Mask Airway (FLMA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard Laryngeal Mask Airway (LMA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: LMA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FLMA
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FLMA and LMA
Number of subjects: 20
Study: 7781936

Group type: EXPERIMENTAL
Intervention: Antibiotic group (500 mg amoxicillin q.i.d. and 500 mg tinidazole t.i.d. for 1 week)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Maintenance group (40 mg famotidine for 6 weeks followed by 20 mg famotidine at bedtime for 6 months)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Antibiotic group
Number of subjects: 119

Group type: COMPARATOR
Intervention: Maintenance group
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Antibiotic group (H. pylori negative)
Number of subjects: 119
Study: 2195108

Group type: EXPERIMENTAL
Intervention: Insulin 3 U/h and glucagon 200 micrograms/h in 5% dextrose with 1% human albumin solution (HAS)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 5% dextrose and HAS alone (Control)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Insulin and glucagon therapy
Number of subjects: 18
Study: 44117

Group type: EXPERIMENTAL
Intervention: tween‐ether‐split‐vaccine
Number of subjects: 207

Group type: COMPARATOR
Intervention: subunit‐vaccine
Number of subjects: 207
Study: 31650685

Group type: EXPERIMENTAL
Intervention: Open Bite Group (OBG)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Normal Bite Group (NBG)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Deep Bite Group (DBG)
Number of subjects: 90
Study: 31063671

Group type: EXPERIMENTAL
Intervention: aripiprazole
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 80
Study: 29100778

Group type: EXPERIMENTAL
Intervention: Treatment with tuberculosis regimen
Number of subjects: 319

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 319
Study: 25892434

Group type: EXPERIMENTAL
Intervention: Biofeedback (4-6 months)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Medical treatment with loperamide and stool-bulking agents (2 months)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combination treatment (biofeedback + medical treatment)
Number of subjects: 64
Study: 23928167

Group type: EXPERIMENTAL
Intervention: Peer-based adherence support intervention
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Other clinic patients (not part of the intervention or control)
Number of subjects: 250
Study: 21362275

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 28
Study: 19920269

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (bimonthly tailored, nurse-administered telephone intervention targeting hypertension-related behaviors)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Home BP monitoring (3 times weekly)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Combined intervention (behavioral intervention plus home BP monitoring)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 636
Study: 17920887

Group type: EXPERIMENTAL
Intervention: Mobile-bearing prosthesis (TMK)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fixed-bearing device (AGC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Unilateral arthroplasty with TMK
Number of subjects: 40
Study: 15657164

Group type: EXPERIMENTAL
Intervention: Complementary and alternative medicine (CAM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contemporary medical practice
Number of subjects: 0
Study: 11923755

Group type: EXPERIMENTAL
Intervention: Injection therapy with epinephrine‐polidocanol (1%)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Hemoclip application
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Injection combined with hemoclip
Number of subjects: 101
Study: 9874432

Group type: EXPERIMENTAL
Intervention: Ranitidine (3 x 50 mg intravenously)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Pirenzepine (3 x 10 mg intravenously)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 7711365

Group type: EXPERIMENTAL
Intervention: Treatment for chronic low-back pain
Number of subjects: 456

Group type: COMPARATOR
Intervention: Spinal rotation measurements
Number of subjects: 456
Study: 2560684

Group type: EXPERIMENTAL
Intervention: Glucagon (1 mg s.c.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Insulin (0.2 U/kg i.v., ITT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 1000228

Group type: EXPERIMENTAL
Intervention: Radiant heater group
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Radiant heater group (babies < 1500 g)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Radiant heater group (babies < 1000 g)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Incubator group (babies < 1000 g)
Number of subjects: 56
Study: 31511286

Group type: COMPARATOR
Intervention: Short interval (<3 years) between menarche and first sexual intercourse (FSI) or start of oral contraceptive (OC) use
Number of subjects: 913

Group type: COMPARATOR
Intervention: Long interval (≥3 years) between menarche and FSI or start of OC use
Number of subjects: 913

Group type: COMPARATOR
Intervention: Early age at start of OC use in women with a short interval between menarche and FSI
Number of subjects: 913
Study: 28608926

Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg plus ethanol 0.4 g/kg
Number of subjects: 1543

Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg plus ethanol 0.8 g/kg
Number of subjects: 1543

Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg
Number of subjects: 1543

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1543

Group type: EXPERIMENTAL
Intervention: Flibanserin 100 mg plus ethanol
Number of subjects: 1543
Study: 26392753

Group type: EXPERIMENTAL
Intervention: Sibutramine (daily 12.55 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 24313577

Group type: EXPERIMENTAL
Intervention: Camouflage Syringe
Number of subjects: 0
Study: 21649532

Group type: EXPERIMENTAL
Intervention: Fermented milk product containing Ile-Pro-Pro and Val-Pro-Pro (25 mg peptides and 2 g plant sterols)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 19293009

Group type: EXPERIMENTAL
Intervention: Phenol peels
Number of subjects: 46
Study: 17129925

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (stress inoculation training)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Pharmacological treatment (cyclobenzaprine)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Combined pharmacological and cognitive-behavioral treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 28
Study: 14715848

Group type: EXPERIMENTAL
Intervention: Genistein (54 mg/d)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (1 mg/d 17beta‐estradiol combined with norethisterone acetate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 11692292

Group type: EXPERIMENTAL
Intervention: Rifaximin (400 mg twice per day)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Ciprofloxacin (500 mg twice per day)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 187

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 187
Study: 9134917

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate beverage
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 30
Study: 7950180

Group type: EXPERIMENTAL
Intervention: Jian Yan Ling (JYL)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 3110804

Group type: EXPERIMENTAL
Intervention: 3 g L-carnitine daily for 3 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 4 g L-carnitine single oral dose
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29729237

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg nightly)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 28760798

Group type: EXPERIMENTAL
Intervention: Elastomeric infusion pump (Baxter Infusor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electronic infusion pump (ambIT Continuous)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both pumps
Number of subjects: 0
Study: 26277548

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (70 IU/kg body weight/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 22946487

Group type: EXPERIMENTAL
Intervention: Metyrapone (750 mg) with MDMA (75 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: MDMA (75 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17

Group type: COMPARATOR
Intervention: Metyrapone (750 mg)
Number of subjects: 17
Study: 21958886

Group type: EXPERIMENTAL
Intervention: 600-mg clopidogrel loading dose
Number of subjects: 201

Group type: COMPARATOR
Intervention: 300-mg clopidogrel loading dose
Number of subjects: 201
Study: 18400718

Group type: EXPERIMENTAL
Intervention: n-3 fatty acid eicosapentaenoic acid (EPA) capsules (1.5 g/d) for 6 months
Number of subjects: 52

Group type: COMPARATOR
Intervention: No supplement (controls)
Number of subjects: 52
Study: 17409863

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (100 mg/m for 3 of 4 weeks) and carboplatin (AUC = 6 mg/ml/min once every 4 weeks)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Weekly paclitaxel or observation as maintenance therapy after four cycles of chemotherapy
Number of subjects: 403
Study: 12725879

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg dry powder
Number of subjects: 921

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 921
Study: 10776684

Group type: EXPERIMENTAL
Intervention: Mud packs and sulfur baths in addition to daily exposure to sun ultraviolet rays and regular bathing at the Dead Sea (Group 1)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Daily exposure to sun ultraviolet rays and regular bathing at the Dead Sea (Group 2)
Number of subjects: 42
Study: 8737630

Group type: EXPERIMENTAL
Intervention: Oxerutins (2 x 500 mg daily)
Number of subjects: 133
Study: 1568584

Group type: EXPERIMENTAL
Intervention: 10 mg MK-329
Number of subjects: 6
Study: 3158321

Group type: EXPERIMENTAL
Intervention: Desogestrel (DG) 125 micrograms/day for 3 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LN) 125 micrograms/day for 3 weeks
Number of subjects: 30
Study: 31822925

Group type: EXPERIMENTAL
Intervention: Inhalation of vaporized synthetic 5‐methoxy‐N,N‐dimethyltryptamine
Number of subjects: 11
Study: 30352583

Group type: EXPERIMENTAL
Intervention: Physical activity group
Number of subjects: 1298

Group type: COMPARATOR
Intervention: Health education group
Number of subjects: 1298
Study: 27094716

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 84
Study: 24952865

Group type: EXPERIMENTAL
Intervention: Cystatin C levels (measured in plasma within 24 hours of admission)
Number of subjects: 16279

Group type: EXPERIMENTAL
Intervention: Cystatin C or genotype‐adjusted cystatin C levels
Number of subjects: 16279

Group type: EXPERIMENTAL
Intervention: Combined endpoint (CV death or MI)
Number of subjects: 16279
Study: 22633251

Group type: EXPERIMENTAL
Intervention: SOM-A (original MOVE program)
Number of subjects: 44

Group type: COMPARATOR
Intervention: SOM-B (self-guided MOVE curriculum)
Number of subjects: 44
Study: 21189766

Group type: EXPERIMENTAL
Intervention: Prop‐based oral health and nutrition intervention program (8‐10 minute duration)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall group (both intervention and control)
Number of subjects: 90
Study: 18721121

Group type: EXPERIMENTAL
Intervention: Acu-TENS
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo-TENS
Number of subjects: 46
Study: 15955217

Group type: EXPERIMENTAL
Intervention: Terlipressin 2 mg after somatostatin 250 microg/h
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Somatostatin 250 microg/h
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Somatostatin plus Terlipressin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Terlipressin alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Somatostatin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 24
Study: 12802125

Group type: EXPERIMENTAL
Intervention: Kabat‐Zinn's mindfulness‐based stress reduction program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 10735579

Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resiniferatoxin (RTX)
Number of subjects: 0
Study: 8679357

Group type: EXPERIMENTAL
Intervention: 0.5% lignocaine 3 mg kg‐1
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 10
Study: 2049321

Group type: EXPERIMENTAL
Intervention: Mantle radiotherapy followed by six cycles of adjuvant MVPP (RT + MVPP)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Mantle radiotherapy alone (RT)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Overall treatment (RT + MVPP)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Overall (RT + MVPP and RT)
Number of subjects: 115
Study: 6344698

Group type: EXPERIMENTAL
Intervention: Enflurane, 0.7% end‐tidal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Halothane, 0.4% end‐tidal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Innovar, 0.1 ml/kg, intravenously
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Morphine, 0.5 mg/kg, intravenously
Number of subjects: 24
Study: 30869980

Group type: COMPARATOR
Intervention: CMA (Contingency Management for Abstinence)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: CMS (Contingency Management for Shaping cessation)
Number of subjects: 110
Study: 29759832

Group type: EXPERIMENTAL
Intervention: MultiPoint Pacing (MPP)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Bi-V pacing
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: MultiPoint Pacing (MPP) - MPP-AS
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: MultiPoint Pacing (MPP) - MPP-Other
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Overall safety of CRT-D system
Number of subjects: 381
Study: 26087570

Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer/fluoride dentifrice (0.3% triclosan, 2.0% copolymer, 1,450 ppm F)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Herbal/bicarbonate dentifrice (herbal extract, 1,400 ppm F)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Fluoride dentifrice (450 ppm F, 1,000 ppm F as sodium monofluorophosphate)
Number of subjects: 135
Study: 23358446

Group type: EXPERIMENTAL
Intervention: Early percutaneous coronary intervention (E-PCI)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Selective PCI (S-PCI)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 224